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Abstract
MRI plays important roles in endometrial and cervical cancer assessment, from detection to recurrent disease evaluation.
Endometrial cancer (EC) is the most common malignant tumor of the female genital tract in Western countries. EC
patients are divided into risk categories based on histopathological tumor type, grade, and myometrial invasion depth. EC
is surgically staged using the International Federation of Gynecology and Obstetrics (FIGO) system. Since FIGO (2009) stage
correlates with prognosis, preoperative staging is essential for tailored treatment. MRI reveals myometrial invasion depth,
which correlates with tumor grade and lymph node metastases, and thus correlates with prognosis. Cervical cancer (CC) is
the second most common cancer, and the third leading cause of cancer-related death among females in developing
countries. The FIGO Gynecologic Oncology Committee recently revised its CC staging guidelines, allowing staging based
on imaging and pathological findings when available. The revised FIGO (2018) staging includes node involvement and
thus enables both therapy selection and evaluation, prognosis estimation, and calculation of end results. MRI can
accurately assess prognostic indicators, e.g., tumor size, parametrial invasion, pelvic sidewall, and lymph node invasion.
Despite these important roles of MRI, radiologists still face challenges due to the technical and interpretation pitfalls of MRI
during all phases of endometrial and cervical cancer evaluation. Awareness of mimics that can simulate both cancers is
critical. With careful application, functional MRI with DWI and DCE sequences can help establish a correct diagnosis,
although it is sometimes necessary to perform biopsy and histopathological analysis.
Keywords: Endometrial cancer, Cervical cancer, Magnetic resonance, Diffusion, Lymph nodes
Keypoints
 MRI of endometrial and cervical cancer facilitates
patient stratification into treatment groups.
 MRI acquisition and interpretation errors can lead
to diagnostic and staging mistakes.
 In endometrial and cervical cancer, DWI, and DCE
improve staging accuracy and tumor delineation.
 For both endometrial and cervical cancer, assessing
lymph node involvement plays an important role.
Compared to CT and MRI, 18fluorine-18
fluorodeoxyglucose PET-CT (18F-FDG PET-CT) is
more accurate for the detection of nodal metastasis
larger than 10mm.
Introduction
At most institutions, the clinical use of MRI remains lim-
ited to specific clinical questions and selected patients.
Notably, in cases of endometrial and cervical cancer, MRI
offers the best diagnostic accuracy for staging and asses-
sing lymphadenopathies, defining advanced disease, plan-
ning radiation ports, monitoring treatment response, and
post-treatment surveillance to detect recurrence [1, 2]. In
this context, MRI plays an important role in guiding pri-
mary treatment and reportedly improves patient outcomes
[2–15].
Conventional MRI is useful for assessing the anatom-
ical details of pelvic structures, but also has limitations
and pitfalls [4, 7, 11, 16]. In the present review, we
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aimed to describe the important roles of MRI in endo-
metrial and cervical cancer and to highlight the most
common MRI pitfalls and mimickers, to help avoid mis-
takes that may impact patient management.
Endometrial cancer
Endometrial cancer (EC) is the most common malignant
tumor of the female genital tract in Western countries.
Most cases are diagnosed at an early stage, and 75% occur
in postmenopausal women (> 50 years) with vaginal bleed-
ing being the main symptom [1, 4, 7, 8]. Risk factors in-
clude conditions promoting increased estrogen exposure,
such as hormonal replacement therapy, obesity, tamoxifen
use, early menarche, late menopause, nulliparity, history
of polycystic ovary disease, and hereditary non-polyposis
colorectal cancer (Lynch syndrome type 2) [3, 6, 17–19].
EC is categorized into two histopathological subtypes:
type I (80–85%) and type II (10–15%). Type I is
estrogen-dependent, affects younger patients (premeno-
pausal or perimenopausal women), and is usually diag-
nosed at an early stage due to abnormal vaginal
bleeding. Histologically, type I EC is a grade 1–2 endo-
metrioid adenocarcinoma with a good prognosis (5-year
survival, 80%). On the other hand, type II EC affects
older women (postmenopause), is more commonly diag-
nosed at an advanced stage (60%) and can lead to the
development of peritoneal carcinomatosis (as also occurs
in ovarian cancer). Histologically, type II EC includes
grade 3 endometrioid adenocarcinomas and other rare
etiologies, such as clear cell carcinoma, undifferentiated
serous carcinoma, and carcinosarcoma. Type II EC ex-
hibits aggressive behavior and a poor prognosis (5-year
survival, 40%) [4, 8, 17–19].
Recurrence is defined as tumor regrowth and/or the pres-
ence of distant disease after treatment. Early detection of
recurrent disease is critical for establishing a therapeutic
strategy with curative intent. Therefore, it is important to
identify patients with a high risk of recurrence. Risk factors
include advanced stage at diagnosis, high-grade disease,
and lymphovascular space invasion (LVSI). Tumor recur-
rence typically occurs within 3 years after surgery (87%),
with the most common recurrence sites being the vaginal
vault (42%) and regional lymph nodes (LNs) (46%) [20].
Cervical cancer
Cervical cancer (CC) is the second most commonly
diagnosed cancer and the third leading cause of
cancer-related deaths among females in developing
countries. CC most often affects women between 45 and
55 years of age. Rates of CC show large geographic vari-
ation, reflecting differences in screening availability and
in the prevalence of human papillomavirus (HPV) infec-
tion (particularly the oncogenic subtypes, e.g., HPV 16
and 18), which is detected in 99% of cervical tumors [10,
11, 17, 18, 21].
Squamous cell carcinoma comprises approximately 69%
of all cervical cancers. The second most common type is
adenocarcinoma, accounting for approximately 25% of
CC. The remaining cases comprise rare histological types,
including small cell neuroendocrine carcinoma and other
epithelial tumors [17, 18]. The histological subtype and
differentiation grade determine the disease course, the
therapeutic outcome, and patient survival [17, 22, 23].
Though this remains controversial, the majority of studies
show worse survival with adenocarcinomas compared to
squamous cell carcinomas, with 10–20% differences in
5-year overall survival rates [24].
In cases of CC, 60–70% of post-treatment recurrences
occur within 2 years post-treatment and 89–98% within
5 years after treatment. The four factors that most
strongly predict recurrence are size greater than 3 cm,
adenocarcinoma type, LVSI, and deep stromal invasion
[10]. The most frequent recurrence sites are the pelvis
(vaginal vault, cervix, parametrium, and pelvic wall) and
the paraaortic LNs [25, 26].
Role of MRI in endometrial and cervical cancers
Detecting and staging endometrial cancer
In patients with abnormal vaginal bleeding, the endo-
metrium is initially evaluated by transvaginal ultrason-
ography (TVUS). In postmenopausal patients with
metrorrhagia, focal, or diffuse endometrial thickening
of > 4 mm should be considered suspicious [27].
TVUS can be helpful in preoperative staging, showing
an overall accuracy of 60–76% with regards to asses-
sing the degree of myometrial invasion. It is also use-
ful for evaluating cervical involvement, having a
diagnostic accuracy comparable to contrast-enhanced
MRI. Definitive EC diagnosis requires endometrial bi-
opsy or dilation and curettage [3, 8, 27].
MRI is the best tool for preoperatively assessing myo-
metrial invasion depth and cervical involvement—which
correlate with tumor grade, presence of LN metastases,
and overall survival [4, 8, 19]. The American College of
Radiology recommends MRI as the preferred imaging
modality for treatment planning, while the National
Comprehensive Cancer Network (NCCN) guidelines ad-
vise MRI only in cases of type II endometrial cancer or
suspected cervical invasion [28, 29]. The European Soci-
ety of Urogenital Radiology (ESUR) recommends MRI in
cases of type I endometrial carcinoma to identify pa-
tients with stage IA disease who would not benefit from
lymphadenectomy, in cases of type II carcinomas to de-
tect extrauterine spread, and in patients of childbearing
age with grade 1 endometrioid adenocarcinoma to iden-
tify those with endometrium-confined disease who could
benefit from fertility-sparing treatment [8].
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EC is surgically staged using the International Feder-
ation of Gynecology and Obstetrics (FIGO) (2009) and
TNM (8th Edition) systems (Table 1) [30, 31]. Although
FIGO stage correlates with prognosis, preoperative staging
is essential for tailored treatment. The standard surgical
staging procedure includes hysterectomy, bilateral
salpingo-oophorectomy, LN dissection, peritoneal wash-
ing, and omental biopsies. Patients with an intermediate
or high risk of LN metastasis (type I EC with myometrial
invasion of ≥ 50% or type II EC) benefit from lymphade-
nectomy [4–6, 8]. The European Society of Medical
Oncology (ESMO) guidelines do not recommend lymph-
adenectomy in low-risk patients (type I EC with myome-
trial invasion of < 50%).
Computed tomography (CT) can detect pathological
LNs and metastatic disease beyond the pelvis.
Fluorine-18 fluorodeoxyglucose (18F-FDG) PET-CT is
useful for detecting distant metastatic deposits (sensitiv-
ity of 100% and specificity of 94%) and assessing nodal
disease [32].
Detecting and staging cervical cancer
Until 2018, CC was clinically staged based on the
FIGO 2009 classification. However, in 2018, the FIGO
Gynecologic Oncology Committee made revisions to
allow stage assignment based on imaging and patho-
logical findings, when available [26]. Table 2 shows
the revised staging (FIGO 2018) and TNM (8th Edi-
tion) classifications [26, 31].
Stage IA1 and IA2 cancers are diagnosed by microscopic
examination of specimens from a loop electrosurgical exci-
sion procedure or cone biopsy. They can also be diagnosed
from trachelectomy or hysterectomy specimens. Clinically
visible lesions (stage 1B and higher) are diagnosed by punch
biopsy. Some cases may require performance of a small
loop biopsy or cone biopsy [26]. The revised FIGO staging
also permits the use of available imaging modalities (ultra-
sound, CT, and MRI) to obtain information regarding
tumor size, nodal status, and local or systemic spread [26].
In experienced hands, TVUS is highly accurate for
evaluating cervical stroma infiltration in patients with
early-stage CC. TVUS may also identify complications of
local-regional invasion, such as hydronephrosis or endo-
metrial cavity distension secondary to cervical canal ob-
struction by the tumor. On the other hand, the limited
soft-tissue contrast and the small field of view (FOV)
may lead to suboptimal evaluation of parametrial inva-
sion, and therefore, TVUS plays a limited role in staging
patients with CC [3].
MRI is the best method for assessing primary tumors
over 10 mm in size, since it can accurately determine
tumor size, parametrial invasion, pelvic sidewall inva-
sion, and LN metastasis, with up to 95% accuracy for
stage IB or higher [2, 10, 11, 26, 33]. In young patients
who desire fertility preservation, MRI is necessary for
evaluating the potential for conservative procedures. Eli-
gibility criteria for vaginal radical trachelectomy (VRT)
and abdominal radical trachelectomy (ART) include
tumor size (≤ 2 cm for VRT, ≤ 4 cm for ART), and tumor
distance from the internal cervical os (> 1 cm for VRT,
> 0.5 cm for ART) [34]. Young women with larger
tumors (FIGO IB1, IB2) are usually selected for ART or
neoadjuvant chemotherapy plus conservative surgery [10,
35]. ART can also be performed in patients with limited
vaginal access and in selected patients with early-stage
cervical cancer at 15–17 weeks of gestation [36].
Compared to CT and MRI, 18F-FDG PET-CT is more
accurate for the detection of nodal metastasis larger than
10mm, with false-negative results in 4–15% of cases. To
avoid false-positive results (especially in areas with high
prevalences of tuberculosis and inflammation, particu-
larly HIV-endemic areas), metastases can be established
or excluded by fine-needle aspiration or biopsy of large
LNs [26].
The risk of pelvic LN involvement increases with
greater tumor size, from 6% for tumors with a maximal
diameter of < 2 cm to 36% for tumors with a maximal
diameter of > 4 cm [37]. In early-stage disease, 18F-FDG
Table 1 TNM (8th Edition) and FIGO (2009) Classification of
endometrial cancer (from refs. [30, 31])
TNM FIGO Description
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Ia Tumor confined to the corpus uteria
T1a IAa Tumor limited to the endometrium or invading less than
half of the myometrium
T1b
IB Tumor invades one half or more of the myometrium
T2 II Tumor invades cervical stroma, but does not extend
beyond the uterus
T3 III Local and/or regional spread
T3a IIIa Tumor invades the serosa of the corpus uteri or adnexa
(direct extension or metastasis)
T3b
IIIb Vaginal or parametrial involvement
(direct extension or metastasis)
N1,
N2
IIIC Metastasis to pelvic or paraaortic lymph nodesb
N1 IIIC1 Metastasis to pelvic lymph nodes
N2 IIIC2 Metastasis to paraaortic lymph nodes with/without
metastasis to pelvic lymph nodes
T4c IVA Tumor invades bladder/bowel mucosa
M1 IVB Distant metastasis (excluding metastasis to vagina, pelvic
serosa, or adnexa) (including metastasis to inguinal lymph
nodes, intra-abdominal lymph nodes other than
paraaortic or pelvic nodes)
aEndocervical glandular involvement alone should be considered stage I
bPositive cytology must be reported separately without affecting the stage
cThe presence of bullous edema is not sufficient evidence to classify as T4
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PET-CT has a sensitivity of 53–73% and specificity of
90–97% for detecting LN involvement. In more ad-
vanced stages, the sensitivity for detecting paraaortic
node involvement increases to 75%, with 95% specificity
[24]. Moreover, 18F-FDG PET-CT can identify local and
distant metastasis and ensure that the radiation treat-
ment volume encompasses both clinically involved and
high-risk areas [10, 11, 38, 39].
Recent evidence suggests that sentinel LN biopsy
(SLNB), with or without dissection, also has an import-
ant role in CC investigation [24, 39]. According to the
revised FIGO, SLNB is still experimental and more
evidence is needed to support its inclusion in routine
practice. SLNB may be particularly useful in early-stage
cervical cancer (FIGO stage IA, IB1, and IB2). Dual la-
beling using blue dye and radiocolloid increases the ac-
curacy of sentinel LN detection, and a near-infrared
technique using indocyanine green dye has been applied
in robotic surgery and laparoscopy. Pelvic lymphadenec-
tomy must be considered when LVSI is present [26].
ESUR and NCCN guidelines recommend the use of
cross-sectional imaging techniques for staging CC in
stage IB1 or greater [11, 29]. Moreover, the guidelines of
the ESMO and the European Society of Gynaecological
Table 2 TNM (8th Edition) and FIGO (2018) Classification of cervical cancer (from refs. 26, 31)
TNM FIGO Description
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Preinvasive carcinoma
T1 I The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded)
T1a IA Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion < 5 mma
T1a1 IA1 Measured stromal invasion depth of < 3 mm
T1a2 IA2 Measured stromal invasion depth ≥ 3 mm and < 5 mm
T1b IB Invasive carcinoma with measured deepest invasion of ≥ 5 mm (greater than Stage IA), lesion limited to the cervix uterib
T1b1
IB1 Invasive carcinoma with measured deepest stromal invasion of ≥ 5 mm, and greatest dimension of < 2 cm
T1b2
IB2 Invasive carcinoma with greatest dimension of ≥ 2 cm and < 4 cm
- IB3d Invasive carcinoma with greatest dimension of > 4 cm
T2 II The carcinoma invades beyond the uterus, but has not extended into the lower third of the vagina or to the pelvic wall
T2a IIA Involvement limited to the upper two-thirds of the vagina without parametrial invasion
T2a1 IIA1 Invasive carcinoma with greatest dimension of < 4 cm
T2a2 IIA2 Invasive carcinoma with greatest dimension of ≥ 4 cm
T2b IIB With parametrial involvement but not up to the pelvic wall
T3 III The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or
nonfunctioning kidney and/or involves pelvic and/or para-aortic lymph nodesc
T3a IIIA The carcinoma involves the lower third of the vagina, with no extension to the pelvic wall
T3b IIIB Extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause)
Nd IIICd Involvement of pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent (with r and p notations)c
IIIC1d Pelvic lymph node metastasis only
IIIC2d Para-aortic lymph nodes metastasis
T4 IV The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum (the
presence of bullous edema is not sufficient to classify a case as Stage IV)
IVA Spread to adjacent pelvic organs
M1 IVB Spread to distant organs
When in doubt, the lower staging should be assigned
aImaging and pathology can be used, when available, to supplement clinical findings with respect to tumor size and extent in all stages
bThe involvement of vascular/lymphatic spaces does not change the staging. The lateral extent of the lesion is no longer considered
cThe notations of r (imaging) and p (pathology) are added to indicate the findings used to assign a case as Stage IIIC. For example, if imaging indicates pelvic
lymph node metastasis, the stage allocation would be Stage IIIC1r, whereas if confirmed by pathologic findings, the stage would be Stage IIIC1p. The type of
imaging modality or pathology technique used should always be documented
dThe revised FIGO classification was recently published (October 2018). TNM (8th Edition) does not include classification for the new FIGO groups IB3, IIIC1, and
IIIC2. TNM defines only regional lymph nodes, with N0 (i+) indicating isolated tumor cells in regional lymph node(s) no greater than 0.2 mm, and N1 indicating
regional lymph node metastasis
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Oncology, in conjunction with the European Society for
Radiotherapy and Oncology and the European Society of
Pathology, recommend SLNB biopsy and/or dissection
as appropriate [24, 39].
For patients with CC, treatment decisions are made
based on the disease stage and extent of spread. Cervical
cancer is primarily managed by surgery (abdominal and/
or vaginal; laparoscopic or robotic), radiation therapy, and
chemotherapy as adjunct therapy in advanced stages [26].
Microinvasive cervical cancer (FIGO IA)
In cases of stage IA1 without LVSI, the appropriate treat-
ment is conization or VRT. In patients not wishing to pre-
serve fertility, simple extrafascial hysterectomy is performed.
To treat stage IA1 with LVSI, pelvic lymphadenectomy
should be considered, along with modified radical hysterec-
tomy [26].
In cases of stage IA2 tumors, fertility-sparing procedures
include cervical conization with laparoscopic (or extraperito-
neal) pelvic lymphadenectomy, ART, VRT, or laparoscopic
trachelectomy with pelvic lymphadenectomy. For women
not wishing to preserve fertility, pelvic lymphadenectomy is
performed along with modified radical hysterectomy or
more radical surgery. In low-risk cases, adequate surgical
treatment may comprise simple hysterectomy or trachelec-
tomy, with either pelvic lymphadenectomy or SLNB [26].
Invasive cervical carcinoma (FIGO stages IB1, IB2, and IIA1)
Women with tumors of ≤ 4 cm are usually treated with rad-
ical hysterectomy and systematic pelvic lymphadenectomy.
Table 3 MRI protocol for endometrial and cervical carcinoma
Sequence Axial
T1
Sagittal
T2
Sagittal
DWI
Coronal
T2
Axial
T2$
Axial DWI Axial DCE Sagittal DCE Axial T2 Coronal
T2
Sequence TSE TSE EPI TSE TSE EPI FS 3D GRE
T1%
3D FS GRE
T1
SS-FSE& SS-FSE&
TE (ms) 8 100 90 100 100 81 2.3 2.3 70 70
TR (ms) 550 4000 4000 4000 4000 6000 4.5 3.6 1000 1000
Echo train length 4 17 EPI 17 17 EPI – – 55 55
Flip angle (degrees) 90 90 90 90 90 90 10 10 90 90
FOV (mm) 320 200 320 200 200 200 300 300 350 320
Slice Thickness
(mm)
5 3 3 3 3 3 1.75 1.4 5 5
Gap (mm) 0.5 0.3 0.3 0.3 0.3 0.3 – – 0.5 0.5
NEX 1 2 2 2 2 1/2/8/12 1 2 1 1
Matrix size 0.8 × 1 0.6 × 0.7 3 × 3 0.6 × 0.7 0.6 × 0.7 2.6 × 3 1.9 × 1.9 1.5 × 1.8 1.4 ×
1.6
1.4 × 1.6
b values (s/mm2) 0, 800 0, 500, 800,
1000
DWI diffusion-weighted imaging, DCE dynamic contrast-enhanced sequence, TE echo time, TR recovery time, FOV field of view, NEX number of excitations, TSE
turbo spin echo, EPI echo planar, 3D FS GRE T1 3D fat-saturated gradient-echo T1 sequence
We use the same protocol with different angulation in the axial oblique sequence (perpendicular to the endometrial cavity or cervix) or double oblique sequence
(angled in both the sagittal and coronal planes)
%40 dynamics (8 s)
$If the uterus is tilted, we perform double axial plane imaging using sagittal and coronal T2WI sequences
&Single-shot fast-spin echo
Table 4 MRI technical artifacts. Pitfalls and pearls
Artifacts Pitfall Pearl
Motion artifacts
Peristalsis (bladder, bowel)
Limit visualization of the anatomical detail of the
uterus
• Adequate patient
preparation
• Use antiperistalsis
agents
Sequence-specific artifacts while using rapid parallel imaging techniques
such as ASSET (GE units) and SENSE (Phillips units), mSENSE
(Siemens units)
May make image interpretation difficult • Increase FOV
Metal artifacts
- Hip prosthesis
- Surgical clips
Limit visualization of the anatomical detail of the
uterus and pelvic structures
Makes staging more difficult
• Use MARS
sequences
FOV field of view, MARS metal artifact reduction sequences
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For young women desiring fertility preservation and in
FIGO stages IA2–IB1 (tumors ≤ 2 cm), radical trachelec-
tomy (VRT, ART, or minimally invasive) may be performed.
When a vaginal approach is planned, first, the pelvic nodes
are laparoscopically removed and sent for frozen section
analysis to confirm node negativity before proceeding with
the radical trachelectomy. Alternatively, the nodes may be
assessed using conventional pathologic methods, followed
by the radical trachelectomy as a second surgery 1 week
later [26].
Locally advanced CC (FIGO stages IB3, IIA2, IIB, III, and IVA)
For locally advanced CC, the preferred treatment option
is concurrent chemoradiation (CCRT), which includes
external radiation and intracavitary brachytherapy. In
patients with only central disease, without pelvic sidewall
involvement or distant metastasis (stage IVA disease and
pelvic recurrence), pelvic exenteration can be considered
but is usually associated with a poor prognosis [26].
FIGO stage IVB/distant metastasis
CC with distant metastatic disease occurs in about 2% of
cases, and the median survival duration in such cases is ap-
proximately 7months. In patients with positive paraaortic
and supraclavicular nodes, CCRT reportedly elicits a better
response than systemic chemotherapy (69% and 57%, re-
spectively), and thus, CCRT is the elective treatment [26].
MRI technique for endometrial and cervical
cancers
The diagnostic performance of MRI, in terms of obtain-
ing optimal imaging and avoiding pitfalls, depends on
a b c
d e f
Fig. 1 MRI technique artifacts. a Axial oblique T2WI. b, c DWI (b: 1000 and ADC map). Right hip prostheses and rectal air prevent detection of a
small cervical tumor. d–f Axial oblique T2WI and DWI. After rectal air removal and change of phase direction, a tiny cervical cancer tumor is
visible (arrows)
a b
Fig. 2 Planning of MRI sequences in endometrial (a) and cervical (b) cancers. Yellow line indicates the coronal plane, red line indicates the axial
oblique plane
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the use of appropriate sequences, using the correct im-
aging planes, and obtaining the highest contrast and
spatial resolution. Tables 3 and 4 list the details of basic
MRI protocols and most technical pitfalls.
Patient preparation
Prior to examination, it is recommended that patients be
given a questionnaire or asked clinical questions regard-
ing clinical symptoms, time of last menstruation, hormo-
nal medication, and prior surgical procedures [40]. To
improve MRI performance, patients must fast for 4–6 h
and bladder and rectal voiding is advised to reduce mo-
tion artifacts (Fig. 1; Table 4). Motion artifacts from
bowel and uterine peristalsis can be further reduced by
intramuscular or intravenous injection of an antiperistal-
sis agent (hyoscine butylbromide or glucagon).
Patients should be imaged in the supine position,
using 1.5 or 3.0 T MRI equipment with a body, pelvic, or
cardiac phase-array surface coil. Fat saturation bands
should be applied to eliminate motion artifacts from the
anterior abdominal wall [2, 4, 8, 10, 16, 19]. Endorectal
or endovaginal coils can provide high-resolution images
of small cervical tumors, but their small FOV limits the
assessment of large tumors, extrauterine extension, and
pelvic LNs [41]. Vaginal opacification with gel is an op-
tional measure that may be useful in cases with sus-
pected cervical tumor extension into the vagina,
particularly into the posterior vaginal fornix [42, 43].
a b
Fig. 3 FIGO IA endometrial tumor (arrows) with myometrial invasion of < 50% is isointense in T2WI images (a) and well-delineated in fused T2WI-
DWI images (b)
Table 5 MRI in endometrial cancer staging. Pitfalls and pearls
Staging (FIGO) Pitfall Pearl
1. STAGE IA/IB: detection and myometrial invasion
• Small or isointense tumors
• Poor visualization of endometrium and/or
poor tumor-to-myometrium interface:
- Presence of leiomyomas/adenomyosis
- Thin myometrium: postmenopause, cornual
regions, or secondary to a compressive large
endometrial mass
No detection
Underestimation or overestimation of
myometrial invasion depth
- DCE and DWI improve detection of small and
isointense tumors
- DWI improves tumor detection and delineation
- In DCE imaging, the presence of a contiguous
band of subendometrial enhancement excludes
myometrial invasion
2. STAGE II: cervical invasion
Tumor protruding or distending cervical os
Misdiagnosis of cervical invasion - Cervical stroma disruption is necessary for
diagnosis of cervical stromal invasion
- DWI and DCE improve tumor delineation
3. STAGE IIIA
• Coexistent ovarian and endometrial tumor
Misinterpreting stage IIIA as synchronous
cancer and vice versa
- Synchronous ovarian and endometrial cancer
• Uterus: early-stage endometrial cancer with min-
imal or no myometrial invasion
• Ovary: unilateral large mass in the background of
endometriosis or borderline tumor
- Ovarian metastasis (IIIA)
• Uterus: deep myometrial invasion and/or tubal
invasion
• Ovary: smaller mass, bilateral ovarian involvement
4. STAGE IV
Tumor invades bladder/bowel mucosa
The presence of bladder mucosal edema
(bullous edema) is not indicative of
mucosal invasion
- Change the direction of phase and frequency
- A preserved fat plane between the tumor and
bladder or rectum excludes stage IVA
- DWI (DWI+T2WI) and DCE help in tumor
delineation
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T2-weighted imaging
T2-weighted imaging (T2WI) is the mainstay of pelvic
MRI. They are best performed without fat suppression (FS)
due to the inherent contrast between the signal intensity
(SI) of the uterus and the surrounding fat. Thin sections
(3–4mm) and a FOV of 20–24 cm are recommended. For
T2WI, image acquisition must be optimized and angled
perpendicularly to the endometrium or cervix (Fig. 2). To
obtain axial oblique images of a tilted uterus, “double ob-
lique images” angled in both the sagittal and coronal planes
create a “true oblique” that is exactly orthogonal to the
endometrial or endocervical cavities [8]. Axial/coronal
T2WI or T1-weighted imaging (T1WI) from the renal hila
to the pubic bone (36–44 cm) can be useful for assessing
paraaortic lymphadenopathies, hydronephrosis, and bone
metastases [4, 10, 11, 19].
Functional imaging
Diffusion-weighted imaging (DWI) is necessary because
it improves uterine tumor detection and characterization
and the visualization of small implants in peritoneal car-
cinomatosis. The DWI protocol should include at least
one plane, but preferably two planes (axial oblique along
the uterus with the same orientation as axial oblique
T2WI, and sagittal), with a minimum of two b values
(e.g., b = 0, b = 1000). Acquiring T2WI and DWI on the
same plane allows image fusion and optimizes anatomic
correlation. To avoid pitfalls, the images from DWI
should always be evaluated together with the corre-
sponding ADC maps and anatomic images [4, 8, 10, 44].
Dynamic contrast-enhanced (DCE) images are
obtained using a 3D FS gradient-echo (GRE) T1WI se-
quence, following intravenous administration of 0.1
mmol/kg gadolinium at a rate of 2–3mL/s. Images are
traditionally acquired in the axial oblique plane perpen-
dicular to the body of the uterus (EC) or the sagittal
plane (CC). Scanning is performed before contrast injec-
tion and then during multiple phases of enhancement, at
30, 60, 90, 120, and 150 s after the injection. For the de-
tection of cervical stroma invasion while staging an EC,
it is optimal to perform a delayed sequence acquired on
the axial oblique plane, around 4min after injection [2,
4, 8, 11, 19].
Functional imaging in disease prognosis and treatment
response monitoring
DWI and DCE sequences reflect changes in the oxygen-
ation, perfusion, and tissue physiology of the tumor micro-
structure and yield quantitative and semi-quantitative
parameters that can potentially serve as biomarkers of
tumor characteristics. The ADC value and DCE have been
investigated with regards to carcinoma aggressiveness and
are reportedly related to prognosis. In theory, ADC values
a b
Fig. 4 Uterus of postmenopausal woman exhibits myomas and FIGO IA endometrial cancer. Endometrial tumor is not delineated on axial oblique
T2WI images (a) and is well-defined on DWI (b = 1000, ADC map) (arrows) (b)
a b c
Fig. 5 FIGO IB tumor exhibiting left cornual extension. a Axial oblique T2WI. b Coronal T2WI. c Fused T2WI-DW images show endometrial tumor
(arrow), which was difficult to delineate on individual images
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are lower in high-grade tumors due to their increased cellu-
larity and restricted water diffusion [44–50].
In EC, Rechichi et al. [47] used two b values (b = 0, b =
1000) and an ADC value threshold of 1.05 × 103mm2/s to
distinguish endometrial cancer from normal endometrial
tissue. However, they found no correlation between ADC
values and tumor grade. Bonatti et al. [51] recently dem-
onstrated that the presence of deep myometrial infiltration
and a tumor/uterus volume ratio of > 0.13 correlated with
high-grade EC, whereas ADC values were not useful for
predicting the histological grade of EC. Inada et al. [48]
found that using DWI and T2WI improved the staging ac-
curacy of myometrial invasion, with a sensitivity of up to
96%. In a recent meta-analysis of 15 studies including 849
patients, T2WI plus DWI showed superior specificity
(0.947) compared to DCE imaging (0.86; p = 0.0035) [52].
Among CC patients, Somoye et al. [50] demonstrated
that median mid-treatment ADC values were higher in
survivors (1.55 × 10−3 mm2/s) than in non-survivors
(1.36 × 10−3 mm2/s), with a 14% difference. Additionally,
ADC values after 4 weeks of treatment reportedly correl-
ate with volume and clinical response [53, 54]. Patients
treated with neoadjuvant chemotherapy show early in-
creases in ADC values, which negatively correlate with
the proliferating cell nuclear antigen and cell density in
patients who respond, indicating that ADC values are re-
lated to cellular features of the response that precedes
size reduction [54].
Several studies show that high peak enhancement in
pretreatment DCE is associated with tumor regression
and local tumor control. High perfusion before and dur-
ing radiotherapy suggests increased vascularity and high
tumor oxygenation, which are both associated with
better treatment response and prognosis [55–58]. Mayr
et al. [59] demonstrated increased tumor perfusion or
relative SI during early radiation therapy for cervical
cancer, suggesting improved oxygenation of previously
hypoxic cells, which would make radiotherapy more
effective in these tumors. Upon therapy completion,
persistent enhancement at the original cervical tumor
site or in the post-surgical bed likely indicates residual
disease, which is associated with increased risk of
recurrence and poor survival [60].
Functional imaging in follow-up and detection of recurrent
disease
The use of MRI with DCE imaging and DWI aids in re-
current tumor detection and allows differentiation from
postradiotherapy changes [20, 45]. 18FDG PET-CT re-
mains the imaging modality of choice for evaluating LNs
a
b
Fig. 6 Endometrial cancer with endometrial cavity distension. a Axial oblique T2WI. b DCE and parametric map. Disruption of the endometrial–
myometrial zone (arrows) indicates myometrial invasion
a b
Fig. 7 Endometrial cancers visualized by sagittal T2WI. a No cervical invasion; cervical stromal is preserved (white arrow). b Direct cervical
invasion; cervical stroma is invaded (red arrow)
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and distant disease, having a sensitivity of 96% and spe-
cificity of 95% [61].
MRI pitfalls in endometrial cancer
There are several commonly recognized signal character-
istics of EC on MRI. In T2WI, an EC tumor appears as a
diffuse or well-delineated soft tissue mass within the
endometrial cavity, which shows heterogeneous inter-
mediate SI relative to the hyperintense normal endomet-
rium and hypointense myometrium. In DWI, tumors
appear hyperintense at the high b value, with a corre-
sponding hypointense signal on the ADC map. On DCE
images, small tumors may show early enhancement
compared to the normal endometrium, and slower en-
hancement than the myometrium. During later phases,
these tumors may appear hypointense relative to the
myometrium. Using DCE imaging, the presence of un-
interrupted enhancement of the subendometrial zone is
best evaluated at approximately 25–60 s after contrast
injection. Myometrial invasion is best assessed during
the equilibrium phase, at 2.5 min after contrast injection.
An imaging delay of approximately 90 s is the optimal
timing for assessing tumor-myometrium contrast.
Delayed-phase images obtained around 4min after
a b
c d
Fig. 8 Synchronous endometrial and ovarian cancer. Visualization by sagittal T2WI (a) and axial oblique T2WI (b) reveals a large multicystic
ovarian mass (white arrow) and endometrial cancer (red arrow). c, d DCE imaging shows heterogeneous uptake in the ovarian mass (white
arrow) and hypoenhancement in the endometrial mass (red arrow)
a b
Fig. 9 Small cell neuroendocrine tumor with myometrium and cervical invasion visualized by sagittal T2WI (a) and sagittal DCE (b). Vaginal and
pubic metastasis are much better delineated in the DCE sequence (arrows)
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contrast injection are useful for detecting cervical stro-
mal invasion [4, 8, 19, 62, 63].
Staging pitfalls
Detection and myometrial invasion (stage IA/IB)
Local staging of EC requires evaluating the depth of tumor
extension into the myometrium. Myometrial invasion is
almost completely excluded by observation of an intact
low-SI junctional zone on T2WI, and a smooth uninter-
rupted band of early subendometrial enhancement on
DCE images [4, 8]. On the other hand, disruption of this
subendometrial band indicates myometrial invasion. Inva-
sion of < 50% of the myometrial thickness indicates a stage
IA tumor, while invasion of ≥ 50% of the myometrial
thickness indicates a stage IB tumor (Fig. 3) [4, 8, 19].
The following possible pitfalls can result in underesti-
mation or overestimation of myometrial invasion
(Table 5): no detection of isointense tumors on T2WI;
poor endometrial–myometrial interface contrast due to
the presence of fibroids or adenomyosis (Fig. 4); thin
myometrium in cornual regions where myometrial thick-
ness is difficult to measure, especially in older women
who have an atrophic uterus and a less-discernible junc-
tional zone (Fig. 5); and endometrial thinning due to ei-
ther age or endometrial cavity distension (Fig. 6). In all
of these scenarios, DWI and DCE imaging can help to
detect and delineate tumors and to assess myometrial
invasion (Table 5). On T2WI, uterine serosa invasion ap-
pears as an area of intermediate-to-high SI disrupting
the normal smooth contour of the outer myometrium.
Fig. 10 Endometrial hyperplasia visualized by sagittal T2WI (a) and axial oblique T2WI (b). Both images show intracavitary endometrial
proliferation that is hyperintense relative to the myometrium. In panel c, there is no diffusion restriction on b = 1000
a b
c d e
Fig. 11 Endometrial-based tumor visualized with sagittal T2WI (a) and sagittal T2WI+DWI (b) was found to be a carcinosarcoma mimicking endometrial
carcinoma. c–e In another patient, an endometrial stromal sarcoma mimicking cervical cancer is visualized by sagittal T2WI (c), axial T2WI+DWI (d), and
DCE (e), revealing a cervical-centered mass with parametrial invasion and adenopathies (arrows in d)
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On DCE images, loss of the normal rim of enhancement
of the outer myometrium indicates serosal involvement
[4, 8].
Cervical invasion (stage II)
On T2WI, cervical stroma invasion is seen as a dis-
ruption of the normal low SI of the cervical stroma
by the intermediate SI of the tumor. It can be diffi-
cult to ascertain by MRI whether the tumor protrudes
only into the cervical canal or invades the cervical
stroma. Even if a tumor distends the uterine and cer-
vical cavity, invasion is only diagnosed if the cervical
stroma is disrupted. Notably, direct cervical stroma
invasion may occur without endocervical mucosa in-
vasion in cases of adjacent myometrial invasion
(Fig. 7). In DWI, cervical stroma invasion is suggested
by the presence of high SI on high b values and
lower SI on ADC maps disrupting the cervical
stroma. On DCE imaging, cervical stroma invasion is
defined by an interruption of the normal enhance-
ment of the cervical stroma [4, 8, 64].
Adnexal or ovarian metastases (stage IIIA)
Tumors showing direct spread to the adnexa or ovar-
ian metastases are considered stage IIIA disease. In
5–8% of cases, synchronous primary ovarian
Table 6 MRI in cervical cancer staging. Pitfalls and pearls
Staging (FIGO) Pitfall Pearl
1. STAGE IA, IB1 (< 2 cm)
• Very small (< 1 cm) tumors
• Isointense tumors in young women
No detection • DWI and DCE improve detection and delineation of
small tumors
2. STAGE IB3
• Cervical edema and/or inflammation secondary to a
recent biopsy or to cervical/vaginal compression by a
large tumor (> 4 cm)a
Overstaging IB3 as stage IIA in
large and exophytic tumors
Overstaging as FIGO IIB tumor
(parametrial invasion)
• Use vaginal gel to distend vaginal walls
• DWI and DCE improve the accuracy of T2WI for the
evaluation of parametrial invasion
Ancillary findings for parametrial invasion:
• Irregular interface between tumor and parametrium
• Asymmetric tumoral bulge
• Vascular encasement
3. Stage IIB
• Diffuse T2 signal inhomogeneity of the cervical rim due
to complete tumoral invasion, without an evident
parametrial mass
Understaging IIB as IB2–IB3
tumors
• Full-thickness cervical stromal replacement by cancer-
ous tissue may be the only feature associated with
parametrial invasion
• The cervical rim must be thick (> 3 mm) and
homogeneous on T2WI to exclude parametrial
invasion
4. STAGE III
• IIIB
• IIIC
Misinterpreting a benign
hydronephrosis as malignant
ureteral infiltration
Misinterpreting benign
adenopathies as malignant
lymphatic spread
Misinterpreting malignant
adenopathies as other pelvic
masses (ovaries …)
• Review clinical data and symptoms, and use other
techniques (i.e., ultrasound, CT urography, or large-
FOV MRI).
• Review clinical data and symptoms and perform node
aspiration or biopsy whenever possible
• Knowledge of pelvic fascia, peritoneal-extraperitoneal
spaces, and other pelvic structures is critical
5. STAGE IV
Same as in endometrial cancer (see Table 5)
FOV field of view
aThis pitfall can occur with any cervical mass (especially large masses) after biopsy because of peritumoral edema, or due to a false-positive estimation of vaginal
invasion when the vaginal fornix is stretched by a bulky exophytic cervical tumor
a b c
Fig. 12 Pregnant woman with biopsy-confirmed cervical cancer that is not detectable on T2WI (a), but is delineated (white arrows) on DWI
images (b, c)
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carcinoma coexists with endometrial cancer [65].
Some features suggest ovarian metastasis, including
bilateral ovarian involvement, morphological similarity
between ovarian and uterine masses, and a larger
uterine mass compared to the ovarian mass. Other
features are more suggestive of primary synchronous
tumors, such as the presence of a large unilateral
ovarian mass, evidence of precursor ovarian lesions
(e.g., endometriosis), and a low-grade uterine mass
without deep myometrial invasion (Table 5; Fig. 8)
[66, 67].
Vaginal metastasis (stage IIIB)
Tumors that involve the vagina by either direct invasion
or metastatic spread (“drop metastases”) are classified as
stage IIIB tumors. DWI and DCE imaging are particularly
helpful for detecting small cervical and vaginal implants
(Fig. 9).
Bladder and bowel mucosa involvement (stage IVA)
Rectum and bladder wall invasion are best evaluated in the
sagittal plane. Preservation of the fat plane between the tumor
and bladder or rectum excludes stage IVA disease. Proper pa-
tient preparation is important since this anatomic plane may
be difficult to delineate in patients with a full extended
bladder. The presence of bladder mucosal edema (bullous
edema) does not indicate mucosal invasion [2, 4, 8, 19].
Distant metastases (stage IVB)
Malignant ascites and peritoneal implants are more
commonly found in cases of type II endometrial tumors.
DWI can help detect small serosal/peritoneal deposits
that may easily be missed on T2WI.
Recurrence of endometrial cancer
In the follow-up of high-risk patients, CT is routinely
used to identify recurrent disease within the lungs or
LNs. However, the vaginal vault can be difficult to as-
sess with CT, and MRI provides improved soft-tissue
resolution. DWI and DCE imaging are particularly
useful for distinguishing between postradiotherapy
soft-tissue thickening and inflammation or recurrent
disease [6, 20]. 18FDG PET-CT can be used to evalu-
ate patients with clinically suspected recurrent disease
that is not detected by conventional imaging [32].
Mimickers of endometrial cancer on MRI
Benign mimickers
Differentiation between EC versus benign conditions,
such as endometrial hyperplasia or polyps, requires
a b
Fig. 13 a, b Sagittal and axial oblique T2WI with vaginal gel, revealing a cervical carcinoma with vaginal infiltration, seen as disruption of the
hypointense anterior wall (arrow)
a b c
Fig. 14 Tumor visualization with axial oblique T2WI (a), DWI-ADC map (b), and DCE imaging (c) reveals loss of the hypointense cervical rim on
the right lateral aspect of the cervix, with an irregular interface between the tumor and the parametrium (arrow). ADC map shows diffusion
restriction, and DCE imaging reveals enhancement of the right lateral wall indicating early parametrial invasion (arrows)
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careful inspection of T2WI, DWI, and DCE images
(Fig. 10). The ADC values are significantly lower for
EC compared to endometrial polyps and normal
endometrium. Occasionally, a submucosal leiomyoma
may be mistaken for focal thickening of the endomet-
rium and thus considered an endometrial carcin-
oma—especially on TVUS. In this scenario, the low
SI of leiomyomas on T2WI allows differentiation be-
tween these entities.
Malignant mimickers
Malignant mimickers include other endometrial-based
tumors, such as endometrial stromal sarcoma and undif-
ferentiated endometrial sarcoma or adenosarcoma. A
correct diagnosis is made by endometrial biopsy or cur-
ettage and histopathological analysis (Fig. 11).
MRI pitfalls in cervical cancer
The size, location, and extent of cervical tumors can be best
evaluated using high-resolution, non-FS T2WI and DWI
[10]. On T2WI, the tumor shows an intermediate-to-high
SI compared to the uterine smooth muscle or myo-
metrium. On DWI, the tumor exhibits an increased
SI on high-b-value images and a corresponding low
signal on ADC maps. On DCE images, small tumors
exhibit increased early homogeneous hyper-enhancement
relative to the adjacent normal cervix, whereas larger
tumors often show heterogeneous enhancement secondary
to necrosis [10].
Staging pitfalls
Early tumors (stages IA–IB1)
MRI cannot delineate microinvasive tumors and thus
plays no role in the evaluation of stage IA lesions. Recent
a b
Fig. 15 FIGO IB2 cervical cancer, with post-biopsy cervical edema. Biopsy was performed 2 days before MRI. a Axial oblique T2WI shows cervical
cancer with apparent parametrial invasion (arrows). b DWI (b = 1000/ADC map) reveals a delineated tumor (arrows), without parametrial invasion
a b
c
d e f
Fig. 16 MRI reveals FIGO IIIB cervical cancer in a 38-year-old woman with adenomyosis and endometriosis in the left ovary. Visualization by
coronal T2WI (a), axial FS T1WI (b), and sagittal T2WI (c) reveals a mass extending to the left parametrium and involving the left ureter (red
arrows) below the endometrioma (E), with a subsequent hydronephrosis. d, e DWI (b = 1000/ADC map) reveals diffusion restriction of the cervical
mass, with extension to the left ureter. f DCE sequence shows enhancement of the cervical mass and ureter wall
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studies report that MRI has a sensitivity of 90% and speci-
ficity of 98% for the staging of early IB1 tumors. The
addition of DWI and DCE imaging enables the detection
of tumors smaller than 1 cm (Table 6) [2, 32, 68].
Stage IB tumors
Stage IB tumors are now subdivided into three cat-
egories based on the lesion’s maximum diameter:
stage IB1, diameter of < 2 cm and stromal invasion
depth of ≥ 5 mm; stage IB2, diameter of ≥ 2 cm and
< 4 cm; and stage IB3, diameter of ≥ 4 cm (Table 2)
[26]. Acquisition of DWI sequences in the same
plane as T2WI allows direct correlation, which helps
delimit the tumor and improves the detection of
small infiltrative tumors (IB1, IB2). On DCE images,
small tumors may show earlier enhancement than
adjacent stroma [10, 64–66].
In young patients, hormonal changes during the men-
strual cycle may result in a higher SI of the cervix on
T2WI, similar to that of the myometrium. DWI and
DCE improve the delineation and tumor-to-cervical
stromal contrast of small isointense tumors that are dif-
ficult to see on T2WI (Fig. 12) [10, 11, 34, 35].
Vaginal invasion (stage IIA)
Invasion of the upper two-thirds of the vagina corre-
sponds to FIGO stage IIA. Stage IIA tumors are divided
into stage IIA1 (tumors ≤ 4 cm) and stage IIA2 (tumors
> 4 cm) based on prognostic differences between these
groups. MRI shows high accuracy (86–93%) for assess-
ment of vaginal invasion. Vaginal infiltration is identified
by a hyperintense lesion disrupting the hypointense wall
on T2WI and early contrast uptake after contrast ad-
ministration (Table 6) [10, 11, 34].
A false-positive estimation of vaginal invasion usually
occurs when the vaginal fornix is stretched by a bulky
exophytic cervical tumor (FIGO IB3). Intravaginal gel
can be used to improve vaginal fornix evaluation by sep-
arating the vaginal walls, improving the identification of
minimal fornix involvement (Table 6; Fig. 13) [43, 69].
Parametrial invasion (stage IIB)
Tumor extension to the parametrial fat implies disruption
of the hypointense cervical stromal rim, with extension of
nodular or spiculated soft tissue into the adjacent parame-
trium (Fig. 14). MRI shows 88–97% accuracy in appropri-
ately evaluating parametrial extension. High-resolution
T2WI in the axial oblique plane is essential for assessing
a b
Fig. 17 FIGO Stage IVA cervical cancer with bladder invasion. Visualization by sagittal T2WI (a) and coronal T2WI (b) reveals cervical cancer
invading the bladder mucosa (red arrow) and rectouterine space (white arrow)
a b c
Fig. 18 Cervical cancer. a Axial oblique T2WI shows a cervical mass (arrow), with hematometra and ureteral invasion (arrowhead) (IIIB). b Sagittal
T2WI shows loss of the hypointense rim of the posterior bladder wall suggesting invasion (arrows). c T2WI+DWI reveals no invasion of the
bladder wall (arrow)
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the disruption or preservation of the hypointense stromal
rim. Preservation of a stromal rim thickness of > 3mm ex-
cludes parametrial involvement (specificity, 96–99%; NPV,
94–100%) [2, 10, 70, 71]. Notably, in patients exhibiting
full-thickness cervical stromal replacement by cancerous
tissue, diffuse T2 signal inhomogeneity of the cervical rim
may be the only feature associated with parametrial inva-
sion. Therefore, accurate exclusion of parametrial
involvement requires that the cervical rim be thick (> 3mm)
as well as homogeneous [71].
Signs of parametrial invasion can also include ancillary
findings—such as the presence of an irregular interface
between the tumor and parametrium, an asymmetric tu-
moral bulge, and a peri-uterine vessel encasement in low
cervical tumors (Table 6) [2, 10, 70]. Cervical edema
and/or inflammation secondary to a recent biopsy, and
a b c
d e
Fig. 19 Cervical cancer treated with chemotherapy and radiotherapy. a Axial oblique T2WI at diagnosis shows a cervical mass. b, c, d A post-
treatment residual mass (arrows) is detected on the right posterior aspect of the cervix by axial oblique T2WI (b), DCE and a type 3 time-intensity
curve (c) and PET/CT (d). e Axial oblique T2WI at 6 months after treatment establishes cervical and right parametrium fibrosis (red arrow) and
shows no residual mass
a b
dc
Fig. 20 Tunnel clusters visualized by axial oblique T2WI (a), coronal
T2WI (b), sagittal T2WI (c), and DWI-ADC map (d). Clustered cystic
spaces have a round or oval appearance, an absence of invasion of
the deep cervical stroma, and no diffusion restriction (arrow in d)
Fig. 21 Adenoma malignum visualized by axial oblique T2WI (a),
coronal T2WI (b), sagittal T2WI (c), and DCE (d). Multicystic lesions
extend from the endocervical glands to the deep cervical stroma
with solid components, forming a mass (arrows)
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cervical compression by a large diffuse infiltrating tumor,
can be misinterpreted as parametrial invasion, poten-
tially leading to the misdiagnosis of a FIGO IB3 tumor
as FIGO IIB. DWI and DCE imaging can help avoid the
overestimation of inflammation and improve the accur-
acy of T2WI for evaluating parametrial invasion (Fig. 15)
[2, 10, 68].
Stage III
Stage III is now subdivided into three categories.
Stage IIIA disease is characterized by involvement of
the lower third of the vagina, where the normal
hypointense T2W signal of the lower third of the va-
ginal vault is disrupted by a hyperintense tumor.
Stage IIIB tumors exhibit extension to the pelvic wall
and/or hydronephrosis or nonfunctioning kidney.
Other causes of hydronephrosis (i.e., endometriosis or
lithiasis) should be excluded to avoid misdiagnosis of
stage IIB disease (Table 6; Fig. 16) [26]. Stage IIIC
disease is characterized by the presence of positive
adenopathies (FIGO 2018). Stage IIC is further subdi-
vided into IIIC1 (adenopathies located in the pelvis)
or IIIC2 (paraaortic adenopathies) (Table 2). When
large adenopathies are found, inflammatory and infec-
tious diseases (i.e., tuberculosis and HIV) should be
excluded. An accurate clinical history, including all
clinical and analytical data, together with fine-needle
aspiration or biopsy of the LNs, are critical for estab-
lishing a correct diagnosis (Table 6) [26].
Bladder and rectal infiltration (stage IVA)
Tumors extending into the mucosa of the bladder or
rectum are classified as stage IVA. MRI is an accurate
technique for evaluating bladder or rectum involve-
ment, with a sensitivity of 71–100% and specificity of
88–91% [2, 10, 11]. The bladder and rectum are
a b c
Fig. 22 Transitional bladder cancer invading the cervix (star), visualized by sagittal T2WI (a), axial oblique T2WI (b), and T2WI+DWI (c)
a b
c d
Fig. 23 Vaginal vault mass after surgery for cervical carcinoma (white arrows) visualized by sagittal T2WI (a), axial oblique T2WI (b), DWI
(b = 1000, ADC map) (c), and DCE (d). Imaging reveals diffusion restriction and early contrast uptake. Biopsy and histopathology indicated
granulation tissue
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evaluated by cystoscopy and sigmoidoscopy only when
the patient is clinically symptomatic. Cystoscopy is
also recommended in cases showing a barrel-shaped
endocervical growth or where the growth extends to
the anterior vaginal wall [26].
Bladder or rectal invasion is suspected in cases
showing obliteration of the fatty plane between the
cervix and adjacent organs. Tumor presence in the
lumen of the bladder or rectum is an unequivocal
sign of infiltration and should be confirmed by biopsy
and histologic analysis (Fig. 17) [24, 39]. A
vesico-cervical fistula is also a sign of advanced dis-
ease. DWI and DCE allow better detection of fistula
tracts [24, 39, 72]. Bullous edema can lead to false es-
timation of posterior wall bladder invasion (Fig. 18).
DWI and DCE imaging can also help to avoid misin-
terpreting bullous edema as invasion [2, 11, 70].
Distant metastasis (stage IVB)
Stage IVB disease is characterized by the involvement of
the paraaortic or inguinal lymph nodes, liver, lung, and/
or bones [10].
Recurrence of cervical cancer
MRI is the best imaging technique for patient follow-up
and for detecting local recurrence after treatment [2,
11]. On T2WI, recurrent disease manifests as a mass
with intermediate-to-high SI [2, 11]. In patients treated
with radiotherapy, it is essential to differentiate between
post-radiation changes and local recurrence. Administra-
tion of intravenous contrast improves detection of recur-
rence, as recurrence shows early enhancement (45–90 s)
and restriction on DWI sequences, whereas fibrosis
exhibits no significant enhancement or enhances in late
phases. Both tumor recurrence and inflammatory
a b c
Fig. 24 Axial oblique T2W (a) and DWI images (b, c) showing stage IIIC 1 endometrial cancer (white arrow) with metastatic left obturatory lymph
node (red arrow)
a b
c
d
e
Fig. 25 a, b MRI of a 48-year-old woman with known adenomyosis, a previous cesarean section, and FIGO IA1 cervical cancer diagnosed in an
outpatient clinic, including sagittal T2WI (a) and axial oblique T2WI (b). No anomalies are visible in the cervix. The cystic image in the right
obturator space (arrow in b) was interpreted as a right ovary with a small follicle. The patient underwent simple extrafascial hysterectomy with
ovarian removal. Post-surgical histology confirmed FIGO stage IA1 (high-grade squamous cell carcinoma), without LVSI and with a clear surgical
margin. c, d MRI was performed 6 months after surgery, including axial oblique T2WI (c) and coronal MIP-DCE sequence imaging (d). The right
obturator cystic lesion increased in size and in contact with right iliac vessels (arrows). Images also show medial displacement of the right pelvic
peritoneal fascia (red arrowhead) indicating an extraperitoneal origin of the cystic lesion. e 18F-FDG PET-CT shows avid enhancement of the cystic
mass. Lymphadenectomy was performed. Histological analysis showed metastatic adenopathy of cervical cancer
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changes may show hyperintensity at a high b value, but
only recurrent tumors will have lower SI on the ADC
map [73]. These patients may require evaluation by
image-guided biopsy or 18FDG PET-CT (Fig. 19).
Mimickers of cervical cancer on MRI
Both benign and malignant cervical diseases can mimic
CC. MRI is a useful technique for distinguishing be-
tween these entities. Invasion of the cervical stroma,
contrast enhancement, and low values on ADC maps
are highly suggestive of malignancy. However, biopsy is
sometimes necessary.
Benign mimickers
Nabothian cysts are generally incidental findings. They
are hyperintense on T2WI and may have variable T1 sig-
nals. Nabothian cysts typically have no solid enhancing
components. The tunnel cluster is a type of Nabothian
cyst that shows complex cystic dilatation of the endocer-
vical glands (Fig. 20). Identifying solid parts is the key to
differentiating a tunnel cluster from neoplasms with a
cystic component, such as adenoma malignum [74].
Cervical polyps are common in women during the
fifth decade of life and are the most frequent cause of in-
termenstrual bleeding in perimenopausal women. The
classical cervical polyp arises from the cervical canal and
exhibits a predominantly glandular structure with a fi-
brous core [75].
Malignant mimickers
Adenoma malignum (also termed minimal deviation
adenocarcinoma) is a subtype of mucinous adenocarcin-
oma of the cervix, which accounts for 3% of all cervical
adenocarcinomas. It exhibits early dissemination and
poor prognosis. Adenoma malignum has been associated
with Peutz-Jeghers syndrome, ovarian mucinous tumor,
and ovarian sex cord tumor. The most common symp-
tom is a watery vaginal discharge [75, 76].
On MRI, adenoma malignum appears as a multicystic
lesion with a solid component located in the endocervi-
cal glands, which extends to the deep stroma, showing a
very high T2 signal and slight hyperintensity on T1WI.
The solid component may exhibit diffusion restriction
on DWI and enhancement after contrast administration
on DCE imaging (Fig. 21) [76].
Large pelvic tumors of the uterus, rectum, bladder, or
unknown origin can also mimic CC stage IVA disease.
Recto-sigmoidoscopy and/or cystoscopy may be neces-
sary to determine the tumor origin or to exclude sec-
ondary bladder or rectal invasion by CC (Fig. 22).
Mimickers of recurrence
Post-surgical inflammatory lesions—such as granulation
tissue, abscesses, or cicatricial endometriosis—can
simulate relapse. On DWI, they appear as masses with
diffusion restriction, usually in the vaginal recess or
anastomotic area (secondary to the presence of high cel-
lular and blood content). Clinical history, laboratory
findings, and biopsy will help establish the correct diag-
nosis (Fig. 23).
Cervical versus endometrial cancer
It is critically important to distinguish between cervical
and endometrial carcinoma due to differences in staging,
prognosis, and therapeutic approach. In a small number
of patients with bulky uterine masses, conventional bi-
opsy may not be sufficient to establish a cervical or
endometrial origin. In such cases, immunohistochemis-
try may help but no single antibody is entirely specific
for cervical or endometrial cancer. Some MRI features
may discriminate between primary cervical and endo-
metrial carcinomas, such as the presence of an endomet-
rial mass in patients with EC [77]. Tumor epicenter
determination with MRI reportedly shows high accuracy
(up to 88%) for identification of tumor origin [78, 79].
Bourgioti et al. [80] described a MRI scoring system
that discriminates between endometrial and cervical
cancer based on seven features: tumor epicenter (uterine
body or cervix), presence of tumor hypervascularity on
early arterial DCE-MRI, full-depth cervical stromal inva-
sion on T2WI images, mass within the endometrial cav-
ity, distended endometrial cavity with secretions, deep
(≥ 50%) myometrial invasion, and enhancing rim at the
tumor periphery. Based on the possible likelihood ratio
values assigned to each of the above features, this scor-
ing system shows highly accurate tumor origin predic-
tion, with sensitivity up to 96.6% and specificity up to
100%.
Lymphatic dissemination in endometrial and
cervical cancer
For both endometrial and cervical cancer, assessing LN
involvement plays an important role in tumor staging,
treatment planning, and prognosis [5, 8, 10, 24, 26, 39].
Based on LN metastases, endometrial cancer is subdi-
vided into stage IIIC1 (pelvic nodes) (Fig. 24) and stage
IIIC2 (paraaortic nodes) (Table 1). In EC, risk factors for
LN metastases include type II tumors, grade 3 tumors,
LVSI, and deep myometrial invasion [4, 8]. LN metasta-
sis distribution is influenced by EC tumor location. The
middle and lower parts of the uterus drain into the para-
metrium and the paracervical and obturator nodes,
while the upper part of the uterus drains into the com-
mon iliac and paraaortic LNs. Inguinal nodes are not
part of the regional lymphatic drainage pathway for EC
and, thus, if affected, represent stage IV disease. In CC,
FIGO stage IIIC is also subdivided into IIIC1 (pelvic
nodes) and IIIC2 (paraaortic nodes) (Table 2). Lymphatic
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spread of CC occurs along the obturator, external iliac,
internal iliac, common iliac, and paraaortic nodes [26].
For discriminating between benign and malignant
nodes, the most widely accepted criterion is nodal size
(short axis > 1 cm) [34, 35]. MRI has moderate sensitivity
(43%) and specificity (73%) for detection of metastatic
lymph nodes. This is because MRI cannot discriminate
between enlarged inflammatory lymph nodes and meta-
static nodes and exhibits dissatisfactory diagnostic accur-
acy in cases of micrometastases [34, 81].
Malignant infiltration of LNs may also be indicated by
morphologic criteria, such as a spherical shape and irregu-
lar contour, altered SI on T2WI, central necrotic areas,
and nodal group formation. Central node necrosis has a
PPV of 100% for the diagnosis of nodal metastases [34].
Normal ovaries with follicles or small masses, neural
or radicular tumors, and other pelvic masses can be mis-
interpreted as pelvic metastatic adenopathies. This pitfall
can be avoided by careful evaluation of the pelvic struc-
tures; identification of peritoneal spaces, extraperitoneal
spaces, and lymphatic channels; and analysis of clinical
data (Table 6; Fig. 25) [34].
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